ALLOB Phase IIA Spinal Fusion Trial Update

Bone Therapeutics has treated 12 patients in the ALLOB® Phase IIA spinal fusion trial, and reports no safety concerns. One patient cohort of four patients remains to be treated.

Bone Therapeutics seeks to support spinal fusion rates by including the ALLOB allogeneic bone-forming cell product in the procedure. This pilot Phase IIA study will...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us